Risk factor
Good trading liquidity
Profitability factor
Favourable analyst view
About
Sinocare Inc. engages in the development, manufacture, and marketing of diagnosis rapid testing products primarily in the People's Republic of China. It offers SARS-CoV-2 antibody test strip; Safe-Accu blood glucose monitoring systems; Safe-AQ blood glucose monitoring systems; Gold-Accu blood glucose monitoring systems; Safe-Accu UG blood, glucose, and uric acid monitoring systems; Safe-Accu KG blood, glucose, and ketone monitoring systems; and D Nurse mobile glucose meters. The company provides its products for the patients with chronic diseases and diabetes, as well as for healthcare professionals. It also exports its products to 135 countries. Sinocare Inc. was founded in 2002 and is based in Changsha, the People's Republic of China.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E
Target Price
The average target price of 300298.SZ is 23 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc